Nuzzo, Andrea http://orcid.org/0000-0002-1630-6499
Van Horn, Stephanie
Traini, Christopher
Perry, Caroline R.
Dumont, Etienne F.
Scangarella-Oman, Nicole E.
Gardiner, David F.
Brown, James R.
Funding for this research was provided by:
Biomedical Advanced Research and Development Authority (HHSO100201300011C)
Article History
Received: 7 November 2020
Accepted: 2 June 2021
First Online: 15 June 2021
Change Date: 26 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12866-021-02356-2
Declarations
:
: The microbiome analysis was an exploratory endpoint in a Phase 2A clinical trial (ExternalRef removed: ExternalRef removed). Subjects provided written consent in accordance with GCP (Good Clinical Practice) guidelines. Protocols and primary findings for this trial were previously published [CitationRef removed]. The clinical trial was performed at the GSK Investigational Site. La Mesa, California, United States, 91942 and IRB approved. The central IRB for this study (GSK 206899) is available from Aspire IRB, 11491 Woodside Avenue, Santee, CA 92071.
: Not applicable.
: A.N., S.V.H., C.T., C.R.P., and N.E.S-O., are employees of GlaxoSmithKline and hold restricted shares. E.F.D, D.F.G. and J.R.B. were employees and restricted shareholder when this work was completed.